Search

Displaying results 5811 - 5820 of 10000 in total
  1. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  2. Drug

    NCX 950

    go.drugbank.com/drugs/DB05849
    Experimental

    NCX 950, beta2-adrenoceptor agonists is widely used in the treatment of pulmonary diseases.

  3. Drug

    Penimepicycline

    go.drugbank.com/drugs/DB13264
    Experimental

    In the classification of the active ingredients included on this list, the classification document states that tetracycline class antibiotics are of medium importance, and are used in humans [L5620]. … It is mentioned on List A produced by the Government of Canada, which is a list of antimicrobial active pharmaceutical ingredients [L2791].

  4. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    of TAK-117 (MLN1117) in Healthy Participants). … Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  5. Drug

    Adipiplon

    go.drugbank.com/drugs/DB06579
    Investigational

    Adipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.

  6. Drug

    ABT-560

    go.drugbank.com/drugs/DB06093
    Experimental

    ABT-560 is a neuronal nicotinic receptor (NNR) modulator, which has shown promise in preclinical models relevant for the treatment of cognitive deficits.

  7. Drug

    Levotofisopam

    go.drugbank.com/drugs/DB19073
    Investigational

    Levotofisopam is under investigation in clinical trial NCT01519687 (Study of Levotofisopam 50 Mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout).

  8. Drug

    CD68-ET3-LV

    go.drugbank.com/drugs/DB32864
    Investigational

    CD68-ET3-LV is an autologous gene therapy consisting of CD34+ hematopoietic stem and progenitor cells transduced ex-vivo with the CD68-ET3-LV lentiviral vector.

  9. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Synonyms: 1-Aethyl-7-methyl-1,8-naphthyridin-4-on-3-karbonsaeure
  10. Drug

    Oxypurinol

    go.drugbank.com/drugs/DB05262
    Investigational

    Oxypurinol, an inhibitor of xanthine oxidase, is a metabolite of allopurinol.